Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Current Research on Biosciences and Biotechnology

Increasing the capacity of natural killer (NK) cells in fighting advance stage ovarian cancer: A cellular immunotherapy minireview Radiana Dhewayani Antarianto; Fransisca Dela Verna; Lady Feren Pangjaya; Sanya Khaerunnisa; Dinda Shezaria; Tricia Dewi Anggraeni
Current Research on Bioscences and Biotechnology Vol. 2 No. 1 (2020)
Publisher : Institut Teknologi Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.5614/crbb.2020.2.1/SPNZ3413

Abstract

Global Cancer Statistics in 2018 estimated 300,000 new cases of ovarian cancer with 152,000 mortality rate each year. The Indonesian Society of Gynecologic Oncology reported 30% of gynecologic cancer is ovarian cancer, which has a 125, 000 mortality rate each year. Ovarian cancer data in Indonesia showed that 70% of patients were diagnosed with ascites or metastasis beyond the ovaries (stage III or IV). Ovarian cancer is an immunogenic disease with an immunotherapy intervention on the horizon. To assess the potency of stimulated NK cells as ovarian cancer cellular immunotherapy, literature search was collected from NCBI, ScienceDirect and Pubchem database. A total of 19 articles relevant to our search terms were included in this review. NK cells from ovarian cancer ascites exhibit low cytotoxic efficacy but can be restimulated using IL-2 or IL-15. An in vitro study that incubated NK cells with an IL-15 fusion protein enhanced the function of the ovarian cancer ascites’ NK cells or the healthy NK cells against the ovarian cancer ascites cells. Human IL-12-, IL-15- and IL-18-induced memory like (CIML) NK cells, has been proven to increase the elimination of xenograft human ovarian cancer cells over a long period of time in a mouse model. CIML NK cells also showed higher NK cell expansion and an enhanced function in the ovarian cancer ascites’ microenvironment, which was immunosuppressive. Phase I-II clinical trials on NK cell-based adoptive cellular therapies demonstrated limited clinical benefit. The major challenges are obtaining persistent NK cells with anticancer activity.
Comparison of the effect of Sumbawa honey and sucrose as extracellular cryoprotectants on viability, morphology, and phenotype stability of CD34+ hematopoietic stem cells from umbilical cord blood Samuel Febrian Wijaya; Retno Lestari; Inna Rahmawati; Imelda Rosalyn Sianipar; Robby Nuraditya; Iqbal Fasha; Gita Pratama; Radiana Dhewayani Antarianto
Current Research on Bioscences and Biotechnology Vol. 5 No. 1 (2023)
Publisher : Institut Teknologi Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.5614/crbb.2023.5.1/CBWGKPBX

Abstract

Cryopreservation is a common practice for the long-term storage and maintenance of the quality of Hematopoietic Stem Cells (HSC) from Umbilical Cord Blood (UCB). Cryomedium containing 10% DMSO is the standard intracellular cryoprotectant agent (CPA) in HSC cryopreservation. However, DMSO is toxic to both cells and patients during transplantation. Therefore, the concentration of DMSO needs to be reduced by adding extracellular CPAs, such as sucrose or Sumbawa honey. The objective of this study was to compare the ability of Sumbawa honey and sucrose as extracellular CPAs to protect HSC CD34+ during cryopreservation. This in vitro study was designed using cryomedium consisting of 10% DMSO as a control, 5% DMSO + 5% Sumbawa honey, and 5% DMSO + 5% sucrose. The results showed that the cryoprotectant containing 5% DMSO + 5% Sumbawa honey had a positive effect and a significant difference (p<0.05) compared with 5% DMSO + 5% sucrose on the viability and morphology of HSC. However, the mean reduction in phenotype stability as indicated by the decrease in percentage CD34+ in the 10% DMSO (6.90 ± 8.60), 5% DMSO + 5% sucrose (10.60 ± 9.20), and 5% DMSO + 5% Sumbawa honey (8.60 ± 11.50) showed no significant difference (p>0.05). In conclusion, the combination of DMSO and Sumbawa honey was able to maintain the viability, morphology, and phenotype stability of HSC. Therefore, honey can be used as an alternative cryoprotectant for the cryopreservation of hematopoietic stem cells.